Omeros Corporation

408 articles with Omeros Corporation

• Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association

  6/14/2021

  Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA).

• Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction

  6/10/2021

  Omeros Corporation today announced publication of the article “Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission” in the peer-reviewed Journal of Neuroscience.

• Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906

  6/9/2021

  Omeros Corporation today announced preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906.

• Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference

  6/9/2021

  Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week.

• Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA

  5/20/2021

  Omeros Corporation today reported that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The new Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021.

• Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress

  5/13/2021

  Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress.

• Omeros Corporation Reports First Quarter 2021 Financial Results

  5/10/2021

  Omeros Corporation, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases and central nervous system disorders, announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2021, which include:

• Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021

  5/5/2021

  Omeros Corporation, announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021, after the market closes.

• Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration

  5/4/2021

  Omeros Corporation announced that the Centers for Disease Control and Prevention has approved an International Classification of Diseases diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

• Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial

  3/23/2021

  -- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients --

• Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results

  3/1/2021

  Omeros Corporation announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2020, which include:

• Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/11/2021

  Omeros to Present at the 39 th Annual J.P. Morgan Healthcare Conference

• Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA

  11/18/2020

  Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effecto

• Omeros Corporation Reports Third Quarter 2020 Financial Results

  11/9/2020

  Omeros Corporation announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2020, which include:

• Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020

  11/5/2020

  Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Deta

• Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development

  10/28/2020

  Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today for registered participants only by ROTH Capital Partners entitled COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly . The presentation, which is part of a session on immune modulators to ameliorate COVID-19,

• Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA

  10/22/2020

  Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved therapy. Narsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), the

• Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit

  10/16/2020

  Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The presentation about the inhibition of the alternative pathway by targeting MASP-3 was made b

• Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA

  10/15/2020

  Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be presented in a webcast on Thursday, October 22, 2020 at 8:30 a.m. ET by Miguel Perales, M.D, Chief of the Adult Bone Marr

• Omeros to Present at the Cantor Virtual Global Healthcare Conference - Sep 11, 2020

  9/11/2020

  Omeros Corporation announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week.